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ABSTRACT 
Objective: The primary goal of this study was to convert a natural catechin-rich extract into nanoparticles by using a biodegradable and non-toxic 
polymer Eudragit L 100 to address the various biopharmaceutical problems of catechin.  
Methods: Nanoparticles were prepared by emulsion solvent evaporation technique using Eudragit L 100 in increasing concentration. Optimization 
of processing conditions like a selection of organic solvents, diluent and surfactant concentrations, drug and polymer ratio and method of drying to 
increase the biological efficiency were duly attempted. Parameters such as dynamic light scattering, zeta potential, SEM and energy-dispersive X-ray 
spectroscopy were assessed for the evaluation of nanoparticles. 
Results: The entrapment efficiency was found to be between 35-45 % with methanol compared to other organic solvents. The zeta potential values 
of all the formulations were in the range of±30 mV to±60 mV) which confirms moderate to good stability. A rapid or ‘burst’ effect of the drug release 
in pH 6.8 buffer showing 92 % in the first 30 min which gradually decreased to 52 % by the end of 180 min but in the pH 7.4, the release was found 
to be moderate. SEM and DLS indicated particles were of spherical shape lying in a nanometer range of 100 to 200 nm with a proportional influence 
of polymer on the particles size. 
Conclusion: Nanoformulations were found to be more stable and confirmed the presence of major elements such as carbon and oxygen. The 
findings collectively indicate that it may be worthwhile to apply nanotechnology for the design of an advanced oral dosage form for an enhanced 
bioavailability and biological efficacy. 
Keywords: Catechin rich extract, Bioavailability, Bioefficacy, Pharmacokinetics, Eudragit L 100, Nanoformulation 




One of the important plant secondary metabolite belonging to a group of 
flavonoids with diverse health benefits in humans is catechin. They are 
polyphenolic compounds having three hydrocarbon rings consisting of 
six hydroxyl groups at different positions, and the position of hydroxyl 
groups is important for their antioxidant activities other biological 
activities [1, 2]. The prominent sources of catechin include apples, 
oranges, pears, black grapes, blackberries, cherries, raspberries, red 
wine and dark chocolate. Acacia catechu being one of the richest sources 
of catechin has been commercially exploited. Flavonoids have 
demonstrated the multitude of therapeutic effects due to their ability to 
interact with various biochemical activities. Some of the examples 
include, inhibiting enzymatic pathways and enzymes such as aldose 
reductase, cyclooxygenase, xanthine oxidase, lipooxygenase and 
phosphodiesterase. Catechin has gained an immense interest for 
researchers has it is known to have anti-proliferative, antimicrobial, anti-
inflammation, and antioxidant properties, it is also shown to improve 
blood flow and has potential benefits in cardiac health [3-7]. 
Chemoprevention using natural plant-based products or plant 
secondary metabolites are essentially important to reduce the cost 
of cancer therapy and mitigate the side effects of conventional 
cancer therapies. In order to understand the phenomenon of 
pharmacokinetics in human, it is essential to know and analyse the 
pharmacokinetic profiles. Bioavailability of the drug is an important 
criterion for assessing the pharmacokinetics in vitro and efficacy of 
any drug/compound. Catechin is known to regulate the cell 
signalling mechanisms due to their antioxidant activity and their 
capacity to interact with cell signalling proteins and membrane 
proteins, which in turn depends on bioavailability [8]. The 
absorption studies conducted on rats suggested that high quantity of 
oral dosage of catechin is required to achieve optimum serum 
concentration, which accounts to 100 folds more than intravenous 
dosage. Besides higher dosage, slow rate of absorption and rapid 
elimination from systemic circulation was also observed [9]. There 
are very few clinical studies, the very reason being its very low 
bioavailability which might be due to rapid elimination from the 
liver by biliary excretion [10] when administered in vivo [11].  
Low bioavailability of catechin was found to be prominent in most of 
the in vivo research works, but the reason for this is still not clear and 
based on the existing literature, there are minimum efforts to address 
this issue. Hence, the existing problem of low bioavailability, slow 
absorption, and high first-pass effect necessitates the need to develop 
strategies that minimize the dosage and in vivo presentation of 
catechin to achieve maximum therapeutic activity with higher 
bioavailability. Several plant-based bioactive compounds are 
formulated into different dosage forms to overcome these drawbacks. 
Most of the recent studies employ nanotechnology approaches to 
improve the solubility, bioavailability and bioefficacy as it allows the 
use of biodegradable, non-toxic nanoparticles having a higher surface 
to volume ratio to attach or encapsulate natural plant products [12]. 
The main objective of the present research work was to assess 
nanotechnology as a tool to develop nanoparticles of catechin-rich 
extract with a biodegradable and non-toxic methacrylic acid co-
polymer eudragit L 100 to promote better delivery of catechin to the 
target site with sufficient residence time for enhanced bioavailability 
due to improvisation in its physical properties.  
MATERIALS AND METHODS 
Catechin rich extract was a gift sample from Green Chem Herbal Pvt. 
Ltd., Bangalore, India. Sodium lauryl sulphate was procured from Hi 
Media, India. Eudragit L 100, Sodium Hydroxide and Potassium 
Dihydrogen Phosphate were procured from Yarrow Chem Products, 
India. All other chemicals and solvents used for the experiment were 
of analytical/HPLC grade obtained from Merck, Mumbai, India.  
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Size reduction of catechin-rich extract (CRE) 
The Particle size of CRE was initially reduced by triturating the 
samples with pestle and mortar for a sufficient length of time 
ranging from 10 to 15 min. The triturated samples were then 
observed under an optical microscope (Olympus NWF, India). The 
particle size was measured for all the samples before and after 
particle size reduction [13]. 
Standardization of organic solvents for nanoformulation 
Various organic solvents such as ethanol, acetone, methanol, 
propanol and an aqueous solution of 0.1 N NaOH were used for 
preparing nanoformulations (table 1). For the production of 
nanoparticles in bottom-up technology the drug was dissolved in a 
solvent, then added to the non-solvent that causes precipitation of 
the fine drug particles [14]. 
Development of nanoparticles 
Nanoparticles were developed by an emulsion solvent evaporation 
technique [15-17] with necessary modifications (table 1). CRE and the 
polymer Eudragit L-100 were finely triturated in a mortar to reduce the 
size to nano size. Drug and the polymers in the ratios of 1:1, 1:2 and 1:3 
were dissolved in 15 ml of methanol, ethanol, acetone, methanol, 
propanol and an aqueous solution of 0.1N NaOH separately. These 
solutions were sonicated for 30 min using an Ultrasonicator (PCI, 
model.1.5 L 5 OH, Mumbai, India) following which were filtered 
separately using a Whatman filter paper no.44 and mixed thoroughly 
using an electric stirrer (REMI Instruments, India) at 3000 rpm for 20 
min. 5 mg of SLS was added to the solution. After the addition of SLS, 10 
mg/ml aqueous solution of lactose monohydrate was added and 
continuously stirred. The obtained solution was dried in a hot air oven 
(Tempo Instruments, Mumbai, India) maintained at 40 °C±5 °C for 8 h. 
 
Table 1: Different combinations of ingredients used for pre-formulation 
Code Pre-formulation ingredients (Quantity in mg) 
CRE EUD L 100 SLS  Lactose Ethanol Acetone Methanol Propanol 0.1N NaOH 
PF1 100 100 30 100 30 ml - - - - 
PF2 100 100 30 100 - 30 ml - - - 
PF3 100 100 30 100 - - 30 ml - - 
PF4 100 100 30 100 - - - 30 ml - 
PF5 100 100 30 100 - - - - 30 ml 
 CRE: catechin rich extract, SLS: sodium lauryl sulphate, EUD: eudragit 
 
Standardization of method of drying 
Two methods of drying for nanoformulations were adopted i.e., hot 
air oven method of drying and lyophilization [18]. Nanoformulations 
were dried by Hot air oven (Tempo Instruments, Mumbai, India) 
maintained at a temperature of 40 °C±5 °C for 8 h. Freeze drying was 
performed using a Lyophilizer (Christ Martin, ALPHA 1-2 LD PLUS, 
Germany). 
Evaluation 
Determination of drug entrapment efficiency in the formulation 
Using the standard calibration curves the drug entrapment 
efficiency of various pre-formulations (prepared using different 
organic solvents) was determined by accurately weighing 100 mg of 
formulation sample and dissolving it in a suitable buffer in which the 
drug has high solubility. Here, 100 mg of each formulation was 
weighed and dissolved in 100 ml of phosphate buffer pH 6.8 and pH 
7.4 respectively in 100 ml volumetric flasks and the volume was 
made up to 100 ml with respective buffers to get (SS–I) of 1000 
µg/ml and (SS–II) of 50 µg/ml which were spectrophotometrically 
analyzed at 276 nm [14]. 





 X 100 
Standardization of concentration of diluent and surfactant for 
nanoformulation 
Lactose was used as a diluent and sodium lauryl sulphate (SLS) as a 
surfactant in the preparation of nanoparticles. To determine the 
effect of diluent and surfactant used in the pre-formulation samples, 
dissolution studies were carried out in phosphate buffers pH 6.8 and 
pH 7.4. The pre-formulation ingredients used for standardized 
formulation PF3 is mentioned in table 2. 
 
Table 2: Standardization of concentration of diluent and surfactant for PF3 formulation 
Pre-formulation ingredient quantity (mg) 
Catechin rich extract (CRE) 100 
Eudragit L 100 100 
Sodium lauryl sulphate (SLS) 30 
Lactose (aqueous solution) 100 
Methanol 30 
 
In vitro dissolution studies  
In vitro dissolution of nano tablets was carried out for 12 h in pH 6.8 
and pH 7.4 phosphate buffer of 900 ml volume in dissolution 
apparatus (USP XXIII (paddle), Lab India, DS 8000, Mumbai, India) at 
50 rpm maintained at 37 °C±0.5 °C. Sample absorbance was 
measured at 276 nm by using a UV/Visible Spectrophotometer (UV-
1600, Shimadzu, Japan). Percentage drug release was calculated 
using the equation obtained from a standard curve [13]. The final 
standardized nanoformulation ingredients are as shown in table 8. 
Residual moisture content analysis 
The moisture content of nanoformulation after freeze-drying was 
analyzed by Karl Fischer Titration using an Auto-Titrator (Titrasys 
352, Systronics, India). The solvent dimethyl sulphoxide (DMSO) 
was standardized with the help of Karl Fischer reagent to determine 
and eliminate moisture content. The nanoformulation was 
solubilised in the DMSO. To the standardized solvent, a fixed volume 
of the sample solution was added and titrated with Karl Fischer 
reagent [19]. The percentage moisture content was determined by 
the formula given below. 
KF =
Weight of Standard 
KF reagent (ml)
× 10.1556 
Moisture Content (%) =
KF Factor × KF reagent required (ml)
Volume of sample solution (ml)
 
Particle size distribution and polydispersity by dynamic light 
scattering 
The particle size distribution and polydispersity were analyzed by 
a dynamic light scattering (Brookhaven Instruments, Zetapals, 
Germany) [16]. Before measurement, a small number of nano-
particles were suspended in distilled water maintained at 25 °C, 
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the suspension was then dispersed by ultrasonic waves with 
power 120 W for 1 min. Particle size distribution and 
polydispersity of NF1, NF2 and NF3 nanoformulations were then 
assayed by the analytical software. The measurement was 
performed in triplicates. 
Zeta potential measurements  
Zeta potential of all standardized nanoformulations was measured 
to determine the stability of nanoformulations using Zeta Potential 
Analyzer (Brookhaven Instruments, Zetapals, Germany). A sample 
was dispersed in distilled water at 25 °C for a period of 30 sec in a 
quartz cuvette with the electrode dipped inside the distilled water. 
Each sample was run 5 times, and the zeta potential graph was 
obtained using zeta pals software of the Smoluchowski model [16].  
Surface morphology by scanning electron microscopy 
Surface morphology and particle size measurement of the 
nanoparticles was determined by scanning electron microscopy 
(SEM) (Zeiss Ultra 55, Germany) [17-24]. In the analysis, the 
samples were firstly attached to a small piece of the electro-
conductive silicon chip; then gold sputtered using a vacuum gold 
sputter coater. 
Elemental analysis of nanoformulation by energy-dispersive x-
ray spectroscopy  
Various elements present in the nanoformulation were determined 
by energy-dispersive x-ray spectroscopy (EDX), which was attached 
to SEM (Zeiss Ultra 55, Germany). The sample analyzed using EDX 
was NF1. A small part of the sample attached to carbon tape was 
selected by viewing under SEM. This selected portion of the sample 
was analyzed for its elemental composition. Weight (%) and Atomic 
(%) for all the elements present was determined [25].  
RESULTS AND DISCUSSION 
Pre-treatment of the catechin-rich extract by trituration 
Size reduction resulted in smaller particles which were 
beneficial because of an increased surface area or unique shape, 
size, and number. The energy efficiency of this unit operation is 
due to the new surface formed with a considerable reduction in 
size. Most of the solid materials occur in large sizes that are too 
large to be used directly. Hence, such material must be subjected 
to size reduction before use. The reduction mechanism consists 
of deforming the sample until it breaks or tears and such 
breaking may be achieved by applying diverse forces like 
trituration. The particle size of pretreated CRE was initially 
reduced from 198.84±1.104 µm to 41.62±0.832 µm due to 
intense trituration in a mortar and pestle for a considerable 
length of time. The reduction in the particle size, before and after 
trituration, was measured in optical microscopy is indicated in 
the table 3. Hence due to particle size reduction by trituration 
due to, all samples were triturated initially and thereafter 
subjected to preparation of nanoformulations. 
Standardization of organic solvents for nanoformulations 
The pharmaceutically acceptable is less hazardous water-miscible 
solvent, such as methanol, ethanol, chloroform, isopropanol, and 
partially water-miscible solvents ethyl acetate, ethyl formate, butyl 
lactate, triacetin, propylene carbonate, benzyl alcohol, are preferent 
in the formulation over the conventional hazardous solvents, such as 
dichloromethane. The volume of organic solvents in each of the 
coded formulations from PF 1 to PF5 is covered in table 1. Out of five 
formulations developed with different ingredients, especially with 
the same volume of organic solvents separately, PF5 formulation 
found to be sticky in nature and hence was excluded from further 
evaluation.
 
Table 3: Particle size measurements before and after particle size reduction of catehin rich extract 
Trial no. Particle size before triturating (µm)±SD Particle size after triturating (µm)±SD 
1 218.07±2.049 21.63±1.570 
2 261.19±1.028 32.45±0.330 
3 181.91±1.579 54.58±1.176 
4 244.85±0.652 33.93±2.773 
5 182.67±4.233 34.82±0.268 
6 174.40±2.397 44.32±1.940 
7 171.28±1.037 52.9±0.952 
8 185.60±0.756 55.33±2.253 
9 129.38±1.338 38.17±1.216 
10 198.64±0.664 43.94±0.721 
mean±SD 198.84±1.104 41.62±0.832 
 The values are expressed as mean±SD; n=3 
 
The particle size of the formulations containing different 
proportions of organic solvents was measured using an optical 
microscope and results are shown in table 3. The mean particle size 
of ethanol, acetone, methanol, and propanol were found to be 
drastically reduced to as low as 40 µm. Table 4 shows that ethanol 
sample has the highest particle size with the mean particle size of 
4.98 µm followed by propanol, methanol and acetone samples 
having a mean particle size of 3.02, 2.98 and 2.95 µm respectively. 
The order of the mean particle size for different organic solvents 
was in the follows Ethanol>Propanol>Methanol>Acetone. Based on 
the above results, propanol, methanol and acetone pre-formulation 
samples were considered for further evaluations. The uniform 
distribution of particles of PF1 (Ethanol), PF2 (Acetone), PF3 
(Methanol) and PF4 (Propanol) was determined by an optical 
microscope. The pictures of ethanol, acetone, methanol and 
propanol pre-formulations captured by the camera fitted to the 
optical microscope are shown in fig. 1-4. It was observed that 
acetone, methanol and propanol pre-formulations showed lesser 
particle size. Methanol and propanol pre-formulations had 
uniformly distributed particles without any aggregation. Thus 
acetone, methanol and propanol pre-formulations were subjected 
for the assay to determine drug entrapment efficiency in pH 6.8 and 
pH 7.4 phosphate buffers. 
Entrapment efficiency 
Based on the results obtained, acetone, methanol, and propanol 
were selected as efficient organic solvents for nanoformulation 
development. Selection of a final organic solvent was done based 
on the evaluation of drug entrapment efficiency in these 
solvents. Methanol pre-formulation showed highest drug 
entrapment efficiency in pH 6.8 and pH 7.4 phosphate buffers 
than in acetone and propanol pre-formulations (table 5). It was 
also observed that an increase in pH of the media from 6.8 to 7.4 
increased the solubility of the drug with higher drug entrapment 
efficiency. Therefore methanol was selected as a choice of an 
organic solvent for preparation of all nanoformulations. The 
percentage entrapment efficiency mainly depends on the nature 
of the drug and polymer. 
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Table 4: Particle size measurement of the pre-formulations 
Trial no.  Sample size (µm) 
Ethanol sample (PF1) Acetone sample (PF2) Methanol sample (PF3) Propanol sample (PF4) 
1 6.40 2.23 4.01 2.00 
2 6.08 4.24 3.63 2.00 
3 3.16 4.12 3.84 1.41 
4 4.12 2.82 2.82 2.01 
5 4.10 3.13 3.32 3.10 
6 5.83 2.23 4.12 3.12 
7 5.65 4.12 3.16 3.16 
8 6.02 1.20 2.23 3.16 
9 6.70 2.82 1.00 4.12 
10 2.22 2.82 3.00 3.23 
mean±SD 4.98±0.331 2.95±0.226 2.98±0.127 3.02±0.214 
The values are expressed as mean±SD; n=3 
 
  
Fig. 1: Optical microphotograph of ethanol pre-formulation Fig. 2: Optical microphotograph of acetone pre-formulation 
  
Fig. 3: Optical microphotograph of methanol pre-formulation Fig. 4: Optical microphotograph of propanol pre-formulation 
 
Table 5: Drug entrapment efficiency of CRE pre-formulation samples in various organic solvents 
Medium Drug entrapment efficiency (CRE) (%) 
Acetone  Methanol  Propanol  
pH 6.8 buffer 21.21 35.96 24.96 
pH 7.4 buffer 34.92 47.42 44.32 
 CRE-catechin rich extract 
 
Standardization of concentration of diluent and surfactant for 
nanoformulation 
Lactose was used as a diluent and sodium lauryl sulphate was used 
as a surfactant in preparing the formulation by emulsion solvent 
evaporation technique (table 6). In vitro dissolution studies were 
carried out two different dissolution solvents pH 6.8 and pH 7.4 
phosphate buffers separately to ascertain the effect of diluent and 
surfactant used in the pre-formulation samples, (table 7 and 8). 
Every ingredient used in the preparation of nanoformulation has an 
effect on the dissolution rate and mechanism of drug release. The 
pre-formulation ingredients used for the nanoformulations areas 
mentioned in table 5. It can be observed that percentage drug 
release was decreasing with increase in time (fig. 8). Also, there was 
a rapid or ‘burst’ effect of the release of drug in pH 6.8 buffer 
showing 92 % in the first 30 min which gradually decreased by the 
end of 180 min (table 7). Almost all the drug content was released in 
the initial 30 min and did not show a sustained release pattern. 
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Similarly in case of pH 7.4 phosphate buffer the drug was released in 
an increasing order from 0 min to 120 min and reached a maximum 
drug release at the end of 120 min after which the % drug release 
decreased (table 8). Sustained release pattern was not observed in 
case of pH 7.4 phosphate. The faster dissolution rate of the Eudragit 
L 100 coated pre-formulation in the initial periods of time was found 
to be due to higher SLS concentration (30 mg/100 mg drug). SLS is a 
surfactant known to increase the dissolution rate significantly which 
can be observed as an initial ‘burst’ effect and subsequent decrease 
in the percentage drug release (fig 5). The rate of release was 
increased with increasing concentration of surfactant. This could be 
due to the emulsification effect of the surfactant after the hydration of 
the nanoparticles by the dissolution medium. Based on the obtained 
results, the concentration of SLS was significantly reduced to obtain an 
optimum sustained release pattern and a final concentration of 5 
mg/100 mg of the drug was used for further nanoformulations. 
  
Table 6: Standardized nanoformulation ingredients and their quantity 
Nanoformulation ingredients Quantity (mg) 
NF1 NF2 NF3 
Catechin rich extract 100 100 100 
Eudragit L 100 (polymer) 100 200 300 
Sodium lauryl sulphate 5 5 5 
Lactose (aqueous solution) 10 10 10 
Methanol (ml) 30 30 30 
Drug: Polymer ratio 1:1 1:2 1:3 
 
Table 7: Dissolution of PF-3 in pH 6.8 buffer  











*The values are expressed as mean±SD 
 
Table 8: Dissolution of PF-3 in pH 7.4 buffer 











n=3 *The values are expressed as mean±SD; n=3 
 
 
Fig. 5: In vitro dissolution profile of PF3 in pH 6.8 and 7.4 
phosphate buffer 
 
Based on previous results, standardized nanoformulation 
ingredients are as shown in table 8. For all the further evaluations 
NF1 with the drug: polymer ratio of 1:1, NF2 1:2 and NF3 1:3 
respectively, were considered. 
Development of optimized nanoformulation 
Nanoformulations of CRE were developed by emulsion solvent 
evaporation technique using Eudragit L 100 as an enteric 
polymer for encapsulation of the drug. Drug and polymer in the 
ratios of 1:1, 1:2 and 1:3 were prepared and evaluated as NF1, 
NF2 and NF3 respectively throughout the study (table 6). 
Nanoformulations were developed by an emulsion solvent 
evaporation technique. The standardized nanoformulation 
ingredients and their quantity are given in table 8. 
Nanoformulations were developed by a simple and cost-effective 
method i.e., emulsion solvent evaporation technique using an 
enteric and biodegradable polymer Eudragit L 100.  
Residual moisture content analysis 
The residual moisture content was determined by Karl fischer 
titration. The residual moisture content of the freeze-dried 
nanoformulation (NF1) was found to be 0.00549 using the equation 
as mentioned in section materials and methods. The negligible 
moisture content as determined indicates that there was very 
negligible moisture content in the nanoformulation. Thus the 
nanoformulation was efficiently dried using lyophilizer. Hot air oven 
method was easier and quicker method compared to lyophilization, 
but the standardization of method of drying was carried out based 
on the evaluation of several parameters such as percentage yield, 
particle size distribution and drug entrapment efficiency in pH 7.4 
phosphate buffer (table 9). The method of drying of 
nanoformulation was standardized by evaluating parameters such 
as percentage yield, the particle size measured by SEM and drug 
entrapment efficiency (table 9). 
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Table 9: Standardization of method of drying 
Code Media/buffer Method of drying Percentage yield (%) Particle size±SD (nm) Drug entrapment efficiency (mg) 
NF1 pH 7.4  Hot air oven 78 241±46.87* 30 
Lyophilization 74 550±72.7** 20 
* The values are values are expressed as mean±SD; n=3, ** The values are expressed as mean±SD; n=5 
 
Based on the results, hot air oven method of drying was found to be the 
most suitable and efficient compared to lyophilization (table 9). NF1 
dried by hot air oven was found to have higher percentage yield content 
and drug entrapment efficiency of 78 % and 30 mg respectively than 
NF1 dried by lyophilization. Most importantly, a freeze-dried sample 
showed a lot of aggregation having to mean particle size of 550 nm 
which is much greater than NF1 dried by hot air oven having a mean 
particle size of 241 nm. This might be due to high vacuum used for 
freeze-drying to dry the moisture content via sublimation process. 
Finally, it dries the sample leaving intact particles which were 
agglomerated. Thus, hot air oven method of drying was standardized as 
the method of drying for preparation of nanoformulations. 
Particle size distribution and polydispersity by dynamic light 
scattering 
Particle size distribution and polydispersity of NF1, NF2, NF3 was 
determined by DLS and are shown in table 10. Nanoformulations 
had a mean particle size ranging from 200 nm to 400 nm and with 
an increase in polymer concentration the particle size increases due 
to the coating of Eudragit L 100 around the drug in multiple layers 
which in-turn depends on polymer concentrations. Hence, the 
particle size is directly proportional to polymer concentration. From 
table 10 it can be observed that all nanoformulations have low 
polydispersity index with uniformly dispersed nanoparticles.  
 
 




Fig. 7: Particle size distribution of NF1 (a), NF2 (b) and NF3 (c) 
 
Surface morphology by scanning electron microscopy 
The scanning electron microscopy revealed the formation of well 
recognizable nanoparticles with uniformity in distribution (fig. 6). 
The examined nanoparticles appeared almost spherical with sharp 
boundaries and a smooth outer surface. Sphericity can be attributed 
to the presence of surfactants due to minimization of surface free 
energy (26). Based on the particle size measurement, nano-
formulations were found within the nanometer range of 100 nm–
200 (fig. 6, 7). SEM also revealed the agglomeration of nanoparticles 
which might be due to the adhesive nature of the polymer and 
drying process of the sample before SEM analysis. 
 
 
Fig. 8: Zeta potential measurement of NF1, NF2 and NF3 
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Zeta potential measurements 
Zeta potential determines the physical stability of nanoparticles in a 
suitable carrier. It is an indirect measurement of the thickness of the 
diffusion layer, i.e., it can be used to predict the long-term stability of 
the nanoformulations. In order to obtain an electrostatically stabilized 
nanosuspensions. In order to obtain an electrostatically stabilized 
nanosuspension exhibiting good stability, a minimum zeta potential 
of±30mv is required whereas, in case of combined electrostatic and 
steric stabilization, a minimum zeta potential of±20mV is desirable. 
Fig. 8 shows the zeta potential measurements of standardized 
nanoformulations and indicates that NF1 has moderate stability 
whereas, NF2 and NF3 have good stability because nanoparticles 
are having high zeta potential (negative or positive) are 
electrically stabilized while nanoparticles with low zeta 
potentials tend to coagulate or aggregate [27]. Increase in 
polymer concentration showed higher zeta potential. This might 
be due to the property of Eudragit L 100 which imparts higher 
stability of the nanoparticles. 
 
Table 10: Comparison of particle size distribution, polydispersity and zeta potential measurements of standardized nanoformulations 
Nano formulation code Particle size distribution* (nm)±SD Polydispersity ±SD Zeta potential* (mV)±SD 
NF1 241±46.8 0.005±0.042 -38.36±2.01 
NF2 334±74.9 0.005±0.045 -46.96±1.14 
NF3 368±73.4 0.051±0.046 -45.84±2.00 
*The values are expressed as mean±SD; n=3 
 
CONCLUSION 
In the present study, Eudragit L 100 was used as a pH sensitive, 
biodegradable and non-toxic polymer. In order to develop a 
biologically efficient nanoformulation, few vital parameters like the 
selection of organic solvents, diluent and surfactant concentrations, 
drug and polymer ratio, a method of drying were standardized. DLS 
data proved that particle size distribution of the nanoparticles 
increases with the increase in the concentration of the polymer. 
Analytical characterization proved the occurrence of the formulations 
in the nanoscale range with optimum stability and drug release. At 
last, it could be reemphasized that the nanotechnology serves as an 
effective tool in the improvement of in vivo efficacy of herbal extracts 
with bioavailability problems and solubility limitations. 
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